BR112017007123A2 - derivados de tetrahidroisoquinolina - Google Patents

derivados de tetrahidroisoquinolina

Info

Publication number
BR112017007123A2
BR112017007123A2 BR112017007123A BR112017007123A BR112017007123A2 BR 112017007123 A2 BR112017007123 A2 BR 112017007123A2 BR 112017007123 A BR112017007123 A BR 112017007123A BR 112017007123 A BR112017007123 A BR 112017007123A BR 112017007123 A2 BR112017007123 A2 BR 112017007123A2
Authority
BR
Brazil
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
modulators
role
benefit
Prior art date
Application number
BR112017007123A
Other languages
English (en)
Other versions
BR112017007123B1 (pt
Inventor
Ates Ali
Valade Anne
Mathieu Benoît
Skolc David
Jnoff Eric
Burssens Pierre
Sands Zara
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112017007123A2 publication Critical patent/BR112017007123A2/pt
Publication of BR112017007123B1 publication Critical patent/BR112017007123B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

a presente invenção se refere a derivados de tetra-hidroisoquinolina de acordo com a fórmula i, que são moduladores alostéricos positivos de d1 e, consequentemente, apresentam benefício como agentes farmacêuticos para o tratamento de doenças nas quais os receptores d1 desempenham um papel.
BR112017007123-1A 2014-10-08 2015-10-06 Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica BR112017007123B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188174.8 2014-10-08
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (2)

Publication Number Publication Date
BR112017007123A2 true BR112017007123A2 (pt) 2017-12-19
BR112017007123B1 BR112017007123B1 (pt) 2023-01-31

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007123-1A BR112017007123B1 (pt) 2014-10-08 2015-10-06 Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica

Country Status (17)

Country Link
US (1) US10105359B2 (pt)
EP (1) EP3204359B1 (pt)
JP (1) JP6622299B2 (pt)
CN (1) CN107001278B (pt)
BR (1) BR112017007123B1 (pt)
CA (1) CA2963951C (pt)
CY (1) CY1123417T1 (pt)
DK (1) DK3204359T3 (pt)
EA (1) EA035544B1 (pt)
ES (1) ES2821821T3 (pt)
HR (1) HRP20201469T1 (pt)
HU (1) HUE050664T2 (pt)
LT (1) LT3204359T (pt)
PT (1) PT3204359T (pt)
RS (1) RS60933B1 (pt)
SI (1) SI3204359T1 (pt)
WO (1) WO2016055479A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510006A (ja) * 2016-02-25 2019-04-11 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
JP6908623B2 (ja) * 2016-04-13 2021-07-28 ユーシービー バイオファルマ エスアールエル テトラヒドロイソキノリン誘導体
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
CA3083329A1 (en) * 2017-12-01 2019-06-06 UCB Biopharma SRL Imaging agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
WO2021001286A1 (en) * 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
JP2022539152A (ja) * 2019-07-01 2022-09-07 ユーシービー バイオファルマ エスアールエル Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
DK4200280T3 (da) * 2020-10-07 2024-03-04 Lilly Co Eli Phenyl-3,4-dihydroisoquinolin-2(1H)-yl-ethan-on-derivater som positive allosteriske modulatorer af dopamin-D1-receptorer
US20240043400A1 (en) 2020-12-03 2024-02-08 UCB Biopharma SRL Octahydroisoquinolinyl Derivatives
CA3202106A1 (en) 2020-12-18 2022-06-23 Adrian Hall Dihydroisoquinolinyl derivatives
JP2024500391A (ja) * 2020-12-18 2024-01-09 ユーシービー バイオファルマ エスアールエル ２－（３，５－ジクロロ－１－メチル－インダゾール－４－イル）－１－［（１ｓ，３ｒ）－３－（ヒドロキシメチル）－５－（１－ヒドロキシ－１－メチル－エチル）－１－メチル－３，４－ジヒドロ－１ｈ－イソキノリン－２－イル］エタノンのプロドラッグ
WO2022129268A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CA3201298A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Amorphous solid dispersions
CA3211261A1 (en) 2021-03-08 2022-09-15 Kevin Michael BIGLAN Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
KR20230154968A (ko) 2021-03-09 2023-11-09 일라이 릴리 앤드 캄파니 파킨슨병 진행을 늦추기 위한 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
US7384957B2 (en) * 2001-12-19 2008-06-10 H. Lundbeck A/S 3,4-dihydro-1H-isoquinolin-2-yl-derivatives
PT1749001E (pt) * 2004-04-29 2010-05-31 Aventis Pharma Inc 3-piperidinilisocroman-5-oles como agonistas da dopamina
RU2009136330A (ru) * 2007-03-01 2011-04-10 Янссен Фармацевтика Н.В. (Be) Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора

Also Published As

Publication number Publication date
HRP20201469T1 (hr) 2020-12-11
RS60933B1 (sr) 2020-11-30
JP6622299B2 (ja) 2019-12-18
CN107001278A (zh) 2017-08-01
CA2963951C (en) 2023-02-28
BR112017007123B1 (pt) 2023-01-31
EP3204359B1 (en) 2020-07-01
SI3204359T1 (sl) 2020-10-30
EA035544B1 (ru) 2020-07-03
DK3204359T3 (da) 2020-09-14
EP3204359A1 (en) 2017-08-16
HUE050664T2 (hu) 2020-12-28
US20170304292A1 (en) 2017-10-26
CY1123417T1 (el) 2021-12-31
PT3204359T (pt) 2020-09-24
JP2017530185A (ja) 2017-10-12
CA2963951A1 (en) 2016-04-14
CN107001278B (zh) 2020-11-24
US10105359B2 (en) 2018-10-23
LT3204359T (lt) 2020-10-12
WO2016055479A1 (en) 2016-04-14
EA201790785A1 (ru) 2017-10-31
ES2821821T3 (es) 2021-04-27

Similar Documents

Publication Publication Date Title
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112017028318A2 (pt) compostos antibacterianos
BR112018076126A2 (pt) compostos heterocíclicos como antibacterianos
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
BR112016014180A2 (pt) reguladores de nrf2
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016004194A8 (pt) compostos úteis como imunomoduladores
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
BR112015022566A2 (pt) composto e composição farmacêutica
UY35469A (es) Moduladores de p2x7
UY35210A (es) Inhibidores de autotaxina
UY34804A (es) Inhibidores del nampt
BR112018075939A2 (pt) compostos heterocíclicos como antibacterianos
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
BR112015023760A2 (pt) compostos e composições terapêuticas
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
BR112017012005A2 (pt) compostos orgânicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2015, OBSERVADAS AS CONDICOES LEGAIS